TABLE 2.
Molecular Data
| ALA | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 74) | No fluorescence (n = 58) | Fluorescence (n = 16) | |||||||||||||||
| Avg | SD | M | n | n/N | Avg | SD | M | n | n/N | Avg | SD | M | n | n/N | P a | ||
| MIB-index % | 4.3 | 4.0 | 3.0 | 4.0 | 3.3 | 3.0 | 5.3 | 5.9 | 4.0 | .242 | |||||||
| WHO 2016 oligo | 12 | 16.2% | 9 | 15.5% | 3 | 18.7% | .859 | ||||||||||
| DA | IDH wildtype | 16 | 21.6% | 12 | 20.7% | 4 | 25.0% | ||||||||||
| IDH mutated | 46 | 62.1% | 37 | 63.8.% | 9 | 56.3% | |||||||||||
| EGFR expression | yes | 6 | 8.1% | 3 | 5.2% | 3 | 18.8% | .057 | |||||||||
| no | 53 | 71.6% | 44 | 75.9% | 9 | 56.2% | |||||||||||
| missing | 15 | 20.3% | 11 | 18.9% | 4 | 0.25% | |||||||||||
| P53 mutation | yes | 22 | 29.7% | 16 | 27.6% | 6 | 37.5% | .294 | |||||||||
| no | 43 | 58.1% | 36 | 62.1% | 7 | 43.7% | |||||||||||
| missing | 9 | 12.2% | 6 | 10.3% | 3 | 18.8% | |||||||||||
| ATRX loss | yes | 20 | 27.0% | 18 | 31.0% | 2 | 12.5% | .100 | |||||||||
| no | 38 | 51.4% | 27 | 46.6% | 11 | 68.8% | |||||||||||
| missing | 16 | 21.6% | 13 | 22.4% | 3 | 18.7% | |||||||||||
| MGMT meth. | yes | 40 | 54.1% | 33 | 56.9% | 7 | 43.8% | .813 | |||||||||
| no | 20 | 27.0% | 16 | 27.6% | 4 | 25.0% | |||||||||||
| missing | 14 | 18.9% | 9 | 15.5% | 5 | 31.2% | |||||||||||
aChi2 for categories and ANOVA for continuous data; avg, average; SD, standard deviation, M, median; DA, diffuse astrocytoma; oligo, oligodendroglioma (1p19q co-deleted); EGFR,epidermanl growth factor receptor; MGMT meth, meythlation of the MGMT promotor gene.